Background {#Sec1}
==========

Obesity, defined as excessive accumulation of body fat, is a complex disorder whose pathogenesis involves both environmental and genetic factors. Obesity, a complex disorder, is a strong predisposing risk factor for several other diseases, like diabetes, hypertension and CAD \[[@CR1]\]. In Pakistan a dramatic increase in the prevalence of obesity has been observed recently and currently 5.2 % females and 1.6 % males in Pakistan over the age of 15 are obese \[[@CR2]\]. As the preventive and therapeutic measures employed so far have failed to bring about the expected results, new pathogenic mechanisms of the disease are being looked for. However, only a small proportion of body mass index (BMI) could be explained on genetic bases due to small effect size of the variants studied \[[@CR3]\]. While some forms of obesity are caused by single mutations, most cases are polygenic and result from a complex interaction between the genotype and the environment \[[@CR4]\].

Coronary heart disease (CAD) is the leading cause of death worldwide. Despite being manageable, the mortality rate is increasing in developing countries and the disease burden is likely to be doubled by 2020 in these countries \[[@CR5]\]. Asian population is more susceptible to heart diseases and a 50 % higher prevalence of cardiovascular diseases has been reported in South Asians \[[@CR6]\]. Pakistan which is a country of \>180 million people has high burden of CAD like rest of the world \[[@CR7]\]. The prevalence of CAD risk factors is high in Pakistani population and more than 30 % of the people above 45 years of age are affected by the disease \[[@CR8]\]

CAD being a complex interplay between environmental, life style and genetic factors, a large number of genes have been investigated for having their role in the development of the disease. As CAD can be a sequel of obesity, the genes involved in the development of obesity have also been investigated of having any role in the development of CAD \[[@CR9]\].

The *FTO* gene has recently become one of the most extensively investigated genes associated with body mass \[[@CR10]\]. It spans more than 400Kb on chromosome 16 and has nine exons \[[@CR11]\]. Despite large size of *FTO* gene, variants implicated in obesity and weight gain are largely located in the first intron \[[@CR12]\]. FTO protein is a 2-oxyglutarate dependent non-heme dioxygenase family member and localizes in nucleus \[[@CR13]\]. Previously *FTO* was thought to be highly expressed in the hypothalamic nuclei involved in energy balance but recent rodent studies suggest that in addition to hypothalamus, it is also expressed in the peripheral tissues like pancreas \[[@CR14]\]. The association of *FTO* variant, rs9939609 with obesity has been confirmed in Caucasians, and the results in Asian populations were initially somewhat conflicting \[[@CR15]--[@CR21]\], however, substantial data on association of this variant with BMI and obesity is now available in Chinese, Japanese, Korean and Filipino populations \[[@CR22]--[@CR25]\]. A meta-analyses of published studies in Asians reported that the minor allele for the rs9939609 significantly (*p* = 9 × 10^−9^) increased the risk of obesity \[[@CR10]\]. Fewer studies in South Asians have been reported, two of which confirmed the association between the *FTO* locus and obesity susceptibility \[[@CR26], [@CR27]\], whereas one study did not \[[@CR28]\].

The association of *FTO* gene variant rs9939609 with CAD has been reported by many studies \[[@CR29]--[@CR31]\]. Though not fully understood, the underlying mechanism of progression to ischemic heart disease involves an array of events like insulin resistance, endothelial damage and inflammation \[[@CR32]\]. Since obesity, metabolic syndrome and CAD are interrelated through a complex interaction of genetic and environmental factors \[[@CR33]\], the SNP has also been reported to be associated with cardiovascular disease \[[@CR34]\]. Keeping in view the importance of this variant in energy metabolism and contradictory results reported so far, we aimed to investigate the association of the *FTO* rs9939609 T \> A single-nucleotide polymorphism (SNP) in Pakistani obese, CAD patients and control subjects and observe the effect of this variant on selected biochemical parameters.

Results {#Sec2}
=======

The baseline characteristics of the study subjects are given in Table [1](#Tab1){ref-type="table"}. A higher proportion of males were having CAD and obesity than females, but the difference was not significant. The CAD cases belonged to an elder age group as compared to controls (*p* = 0.002) whereas the age difference was not significant in obese cases and controls. The lipid profile parameters including TC, LDL-C and TG as well as blood sugar levels were significantly higher in obese and CAD cases as compared to controls. Whereas HDL-C was lower in both cases than control subjects. The genotype call rate was 97 % for obese, 98 % for CAD and 98 % for the control group. The mean weight, BMI and WHR for obese subjects were 96.16 ± 15.95, 36.92 ± 6.46 and 1.00 ± 0.09 respectively, for CHD subjects were 67.13 ± 11.95, 22.46 ± 6.75 and 0.81 ± 0.06 respectively and for control subjects 67.13 ± 9.56, 21.46 ± 9.11 and 0.85 ± 0.10 respectively. Overall, the study population was in Hardy-Weinberg equilibrium (*p* = 0.938).Table 1Baseline features of subjects under studyCharacteristicCADObesityCases (*n* = 425)Controls (*n* = 250)*p*-valueCases (*n* = 295)Controls (*n* = 250)*p*-valueGender (M/F %)59/4154.3/45.70.27156.2/43.854.3/45.70.873Age (years)59 ± 1256 ± 100.00255.32 ± 15.1856.01 ± 10.440.31TC (mmol/L)5.36 ± 1.384.51 ± 1.119.1 × 10^-14^5.54 ± 1.114.51 ± 1.112.0 × 10^-24^TG (mmol/L)2.43 ± 0.832.12 ± 0.743.6 × 10^-8^2.39 ± 0.792.12 ± 0.743.1 × 10^-5^HDL-C (mmol/L)1.11 ± 0.111.74 ± 0.425.9 × 10^-7^1.16 ± 0.311.74 ± 0.421.9 × 10^-66^LDLD-C (mmol/L)2.74 ± 0.742.18 ± 0.432.4 × 10^-5^2.99 ± 0.562.18 ± 0.431.4 × 10^-21^FBG (mg/dL)98.42 ± 6.6189.56 ± 7.291.0 × 10^-46^102.71 ± 14.1289.56 ± 7.292.4 × 10^-31^The table summarizes the general characteristics of the study subjects by comparing the cases with controls. *CAD* Coronary heart Disease group, *TC* Total Cholesterol, *TG* Triglycerides, *HDL-C* High Density Lipoprotein cholesterol, *LDL-C* Low Density Lipoprotein cholesterol, *FBG* fasting blood glucose

Association of FTO rs9939609 polymorphism with obesity and CAD {#Sec3}
--------------------------------------------------------------

The allele and genotype frequencies of the rs9939609 variant are shown in Table [2](#Tab2){ref-type="table"}. The minor allele frequency (MAFs) in CAD group was significantly higher than controls (0.361 vs 0.286. Similarly, the MAF was higher in obese cases than controls (0.381 vs 0.286). Genotype distribution revealed significant differences between the cases and controls (CAD: TT = 44 %, TA = 39.76 %, AA = 16.24 %; obese: TT = 39.32 %, TA = 45.08 %, AA = 15.59 % vs controls TT = 45.2 %, TA = 36.4 %, AA = 18.4 %). Overall, the frequency of TT genotype was 42.88 %, of TA was 40.51 % and of AA was 16.59 %. The *FTO* rs9939609 polymorphism was found to be significantly associated with obesity as well as CAD in Pakistani subjects. The per allele odds ratio (OR) for CAD was 1.43 (1.02--2.01) which is a significant association (*p* = 0.004). Similarly the association with obesity was found to be significant (*p* = 0.0009) with an OR of 1.54 (1.07--2.21).Table 2Allele/genotype frequencies of rs9939609 in study groupGenotype/alleleFrequencyOR (CI), *p*-valueObese (*n* = 295)CAD (*n* = 425)Control (*n* = 250)ObesityCADTT1161871331.54 (1.07--2.21), 0.0009\*1.43 (1.02--2.05), 0.004\*TA13316991AA466926T0.6210.6370.716A0.3790.3630.284The table shows the association of allele/genotype frequencies of rs9939609 in the cases and the control group. *CAD* Coronary Artery Disease group, *OR* Odds Ratio, *CI* Confidence Interval. \*indicates any significant association

Effect of FTO rs9939609 polymorphism on biochemical parameters {#Sec4}
--------------------------------------------------------------

ANOVA was used to check whether the selected variant had any influence on serum biochemical traits (Table [3](#Tab3){ref-type="table"}). The SNP did not appear to affect any of the tested lipid traits to a significant extent. A careful examination of the results revealed that the presence of the risk allele in homozygous state increased triglyceride level slightly when compared to TT or TA genotype in obese subjects and controls, whereas there is a decrease in HDL-C levels in all groups when the AA genotype is compared to TT or TA genotype although the effect is not statistically significant. However, the SNP appeared to be unambiguously associated with fasting blood sugar concentrations in CAD (*p* = 0. 014), obese (*p* = 0.001) and control (*p* = 0.019) groups.Table 3Effect of rs9939609 on biochemical traits in the study subjectsGroupParameterGenotype*p*-valueTTTAAAControls (*n* = 250)Total cholesterol (mmol/L)4.38 ± 1.124.72 ± 1.364.67 ± 0.660.123Triglycerides (mmol/L)2.34 ± 0.662.16 ± 0.752.73 ± 1.220.109HDLC (mmol/L)1.80 ± 0.411.67 ± 0.151.65 ± 0.430.119LDLC (mmol/L)2.13 ± 0.412.25 ± 0.482.26 ± 0.550.187FBG (mg/dL)90.54 ± 6.8190.81 ± 7.9889.81 ± 5.410.019\*CAD (*n* = 425)Total cholesterol (mmol/L)5.41 ± 1.415.30 ± 1.365.38 ± 1.370.735Triglycerides (mmol/L)2.35 ± 0.852.43 ± 0.812.41 ± 0.660.603HDLC (mmol/L)1.15 ± 0.321.18 ± 0.291.16 ± 0.300.795LDLC (mmol/L)2.73 ± 0.722.75 ± 0.732.71 ± 0.850.953FBG (mg/dL)97.14 ± 6.8198. + 1 ± 5.98100.41 ± 6.410.014\*Obese (*n* = 295)Total cholesterol (mmol/L)5.50 ± 0.915.50 ± 0.745.49 ± 0.640.998Triglycerides (mmol/L)2.51 ± 0.762.46 ± 0.752.71 ± 1.050.405HDLC (mmol/L)1.11 ± 0.111.13 ± 0.111.07 ± 0.100.105LDLC (mmol/L)2.96 ± 0.563.04 ± 0.542.95 ± 0.580.552FBG (mg/dL)101.91 ± 13.52104.21 ± 17.65109.92 ± 16.540.001\*The table shows a comparison of mean biochemical parameters for three different genotypes in the study groups with strength of effect indicated by the *p*-value. *CAD* Coronary Artery Heart group, *HDL-C* High Density Lipoprotein cholesterol, *LDL-C* Low Density Lipoprotein cholesterol, *FBG* fasting blood glucose,\*indicates any significant association

Discussion {#Sec5}
==========

We have studied the association of *FTO* polymorphism rs9939609 with obesity and CAD in Pakistani population. Some *FTO* variants already associated with obesity are also associated with CAD risk factors (17). We proposed that since obesity is a well established risk factor for CAD, it is likely that the *FTO* gene, as the BMI/obesity related locus, might confer the risk of CAD. The SNP was found to be significantly associated with both obesity and CAD.

We found the frequency of risk allele (A) was higher in obese cases than controls. The risk allele of rs9939609 was significantly associated with the disease in Pakistani population. It has been reported that the presence of two alleles at the rs9939609 site of the *FTO* gene increased BMI by about 1 kg/m^2^, body mass by 2.3Kg and 1.3-fold higher risk of overweight and obesity in both adults and children. It has been estimated that per unit increase in BMI increase cardiovascular disease morbidity by 8 % \[[@CR35]\]. We found similar results regarding association of the risk allele of rs9939609 with CAD in Pakistani subjects. It is the first study on this variant's effect on CAD in Pakistan and successfully replicated the previous reports. However, the MAF was lower than reported in Caucasians consistent with a previous finding that the prevalence of the risk allele in East Asians (\~20 %) and South Asians (\~30 %) is substantially lower than in Europeans, and the reported effect sizes in both East and South Asians vary widely for BMI (OR 0.13--0.83 Kg/m^2^ per minor allele) and obesity risk (OR 1.02--1.48 per minor allele) \[[@CR36]\]. Regarding the association between *FTO* gene and CAD risk, Doney et al first demonstrated that the A allele of rs9939609 increased the risk of myocardial infarction (MI) in 4897 patients with type 2 diabetes (T2D) in a prospective study, which was independent of BMI, glycohemoglobin, mean arterial pressure, HDL-C, triglycerides, and total cholesterol \[[@CR34]\]. However, the subsequent studies revealed conflicting conclusions \[[@CR31], [@CR37]--[@CR40]\]. A meta-analysis conducted in the end of 2013, comprising 19,153 cardiovascular disease (CVD) cases and 103,720 controls, pooled all these studies together, and found a significant association between the *FTO* gene variant rs9939609 and CVD risk independent of BMI and other conventional CVD risk factors \[[@CR41]\].

The variant did not appear to influence any lipid parameter in the subjects tested, however, showed a consistent association with blood glucose levels. Therefore, it might play a role in progression to CAD through affecting plasma glucose metabolism. This is in accordance with a recent meta-analysis which reported that this variant has no correlation with serum lipid chemistry, and is associated with glucose levels \[[@CR22]\]. However, the mechanism underlying the association of the *FTO* variant with CAD risk remains unclear yet. Previously, the rs9939609 variant was found to influence energy-dense food intake instead of regulation of energy expenditure \[[@CR42]\]. In addition, it was also shown to be associated with diabetes-related metabolic traits (including higher fasting insulin, glucose and triglycerides, and lower HDL cholesterol), although the association disappeared after adjustment for BMI \[[@CR43]\]. Other studies have indicated that *FTO* variant is associated with increased risk for hypertension through the regulation of sympathetic nervous system \[[@CR44]\]. Notably, Hubacek et al believed that the *FTO* variant could increase the risk of CAD through another mechanism, mainly through its possible effect on DNA methylation. In other words, the *FTO* gene variant could interact with an unhealthy lifestyle (such as high fat diet and lack of physical activity), and affect the epigenetic status and ultimately contribute to the development of CVD \[[@CR30]\].

The limitations of the study included a relatively small sample size and inability to include more biochemical and anthropometric measures in order to observe the real behaviour of the variant in the Pakistani ethnic group. The findings of the study should be therefore replicated in larger cohorts in future with more biochemical parameter included in order to validate the results observed in the current investigation and find out new associations, if any, of the variant.

In conclusion, we have shown that the *FTO* variant rs9939609 is associated with obesity and showed for the first time in Pakistan, with coronary artery disease. We confirmed the association of this variant with plasma glucose, but couldn't detect any effect on serum lipid traits.

Methods {#Sec6}
=======

Study subjects {#Sec7}
--------------

A total of 970 subjects were included in the study after obtaining informed consent. The study groups consisted of 295 obese individuals (43.8 % females, 56.2 % males, mean age 39.21 ± 15.18), 425 CAD patients (41 % females, 59 % males, mean age 59 ± 12) and 250 controls (45.7 % females, 54.3 % males, mean age 56 ± 10). The obese subjects were recruited based on BMI and waist to hip ratio (WHR). The BMI cutoffs used were those defined for the Asian population and have been described elsewhere \[[@CR45]\]. An additional measure to differentiate between obese and non obese used was WHR and a value of ≥ 0.85 in females and ≥ 1 in males was used as cutoff \[[@CR46]\]. The CAD patients were selected from tertiary care hospitals of the province of Punjab, Pakistan. These were diagnosed cases based upon the ECG, cardiac echo, radiologic and troponine T/I levels. These cases were recently diagnosed of having CAD and were not taking any lipid lowering or antihypertensive drug. Control subjects were apparently healthy individuals from the general population with BMI 18.5--22.99 Kg/m^2^ and no history of heart disease. The exclusion criteria included the presence of any chronic ailment like chronic liver or kidney disease, cancers or any ongoing acute infection or disease and CAD patients with obesity.

Ethics, consent and permissions {#Sec8}
-------------------------------

All the procedures were in compliance with the Helsinki Declaration and the study was approved by the institutional ethics committee.

Blood sample collection {#Sec9}
-----------------------

Early morning blood samples were collected from the median cubital vein taking aseptic measures. The blood samples were collected into two vacutainers (BD, USA), one coated with EDTA as an anticoagulant and the other containing a gel and clot activator at the bottom. The whole blood sample from EDTA tube was used for DNA extraction, while the clotted blood in gel vials was centrifuged at 5,000rpm for 5min to separate serum. The serum samples were used for determining biochemical parameters.

Determination of biochemical parameters {#Sec10}
---------------------------------------

The serum samples were analyzed for total cholesterol (TC), high density lipoprotein cholesterol (HDL-C) and triglycerides (TG) levels. The end point spectrophotometric methods were adopted according to the manufacturers' guidelines using commercially available kits (Human Diagnostics, Germany). LDL-C was measured by Friedwalds equation. Epoch, Biotek microplate reader (Biotek instruments, Highland Park) was used for all optical density measurements. Fasting blood glucose (FBG) was measured using a digital glucometer (Sky-ERA, TD 4103).

Genotyping {#Sec11}
----------

Genomic DNA was isolated from peripheral blood leukocytes using Promega Wizard® Genomic DNA purification kit. DNA was quantified using nanodrop (ND-8000, USA). The DNA samples were diluted to a standard concentration of 1.25ng/μl. A 4μl of this dilution was taken to get the final working concentration of 5ng of DNA. A liquid handling robotic system (Biomerk FX, Beckman Coulter) was used to spot DNA in 384-well plates (Micro Amp), specially designed for PCR amplification. Genotyping was done by TaqMan allelic discrimination assay using primers and probes given in Additional file [1](#MOESM1){ref-type="media"}: Table S1. The real time PCR reaction mixture consisted of 1X KAPA probe fast qPCR master mix (KAPABiosystems, USA), 100nM of each primer, 100nM of each probe, ROX high (0.4μl/20 μl reaction mixture), 5ng DNA and PCR grade water as needed. The PCR program consisted of an initial temperature of 50 °C for 2 min Then denaturation/enzyme activation at 95 °C for 10 min, finally amplification for 40 cycles each consisting of denaturation at 95 °C for 15s and amplification at 60 °C for1 min. PCR was done on the Bird C1000TM thermal cycler. After amplification the results were analyzed on the ABI Prism 7900HT (Applied Biosystems/Life Technologies) and the genotypes were called using sequence detection software (SDS) version 2.0.

Statistical analysis {#Sec12}
--------------------

Statistical Analysis was done using Statistical Package for Social Sciences (SPSS, IBM statistics, version 22). Independent sample *t*-test was used to compare the anthropometric and biochemical parameters of obese and CHD groups with the controls. The study population was tested for Hardy Weinberg equilibrium and allele/genotype frequencies were calculated. The significance of difference in allele and genotype frequencies was calculated using a chi-squared test. The odds ratio was calculated using binary logistic regression. One-way analysis of variance (ANOVA) was used to check the effect of rs9939609 polymorphism on biochemical parameters. A *p*-value \<0.05 was considered statistically significant for all analyses.

Additional file {#Sec13}
===============

Additional file 1: Table S1.Primers and Probes for TaqMan Assay. (DOCX 10 kb)
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